Panelists emphasize that biomarker evolution has redefined gastric cancer care, demanding early and standardized testing to optimize personalized treatment strategies.

Panelists conclude that biomarker-informed therapy selection has transformed initial treatment decision-making, enabling the alignment of molecular insights with individualized clinical care.

Panelists also outline the principal categories of investigational FGFR2b-targeted treatments, including selective inhibitors, pan-FGFR inhibitors, monoclonal antibodies, and antibody–drug conjugates.

Panelists discuss how recent clinical trials have provided pivotal insights into the efficacy and safety of targeted therapies directed at FGFR2b in gastric cancer.

Panelists discuss how ongoing phase 3 investigations are designed to confirm the efficacy and safety of FGFR2b-directed therapy in a broader patient population.

Panelists discuss how next-generation FGFR2b-targeted agents are advancing the field through innovative molecular engineering and delivery mechanisms.

Panelists discuss how integrating FGFR2b testing into routine diagnostic workflows will be essential to fully realize the benefits of targeted therapy.

Panelists discuss how FGFR2b-directed therapy is expected to play an increasingly prominent role in the evolving treatment landscape for metastatic gastric and gastroesophageal junction cancers.